Platforms, advances, and technical challenges in virus-like particles-based vaccines
Frontiers in Immunology, 2023 Viral infectious diseases threaten human health and global stability. Several vaccine platforms, such as DNA, mRNA, recombinant viral vectors, and virus-like particle-based vaccines have been developed to counter these viral infectious diseases.
Reeshu Gupta +6 more
doaj +1 more source
Virus-like particles as vaccine.
Acta Biochimica Polonica, 2014 This review presents data on commercial and experimental virus-like particle (VLP) vaccines, including description of VLP vaccines against influenza. Virus-like particles are multimeric, sometimes multiprotein nanostructures assembled from viral structural proteins and are devoid of any genetic material. VLPs present repetitive high-density displays of
Jadwiga, Chroboczek +2 more
openaire +3 more sources
Recombinant monovalent llama-derived antibody fragments (VHH) to rotavirus VP6 protect neonatal gnotobiotic piglets against human rotavirus-induced diarrhea [PDF]
, 2013 Group A Rotavirus (RVA) is the leading cause of severe diarrhea in children. The aims of the present study were to determine the neutralizing activity of VP6-specific llama-derived single domain nanoantibodies (VHH nanoAbs) against different RVA strains ...
Alvarado, Carmen +14 more
core +8 more sources
Influenza and memory T cells : how to awake the force [PDF]
, 2016 Annual influenza vaccination is an effective way to prevent human influenza. Current vaccines are mainly focused on eliciting a strain-matched humoral immune response, requiring yearly updates, and do not provide protection for all vaccinated individuals.
Glezen +12 more
core +3 more sources
Influenza virus-like particle vaccines
Expert Review of Vaccines, 2009 Enveloped virus-like particle (VLP) vaccines containing influenza hemagglutinin (HA) and neuraminidase (NA) antigens are produced easily in insect or mammalian cells via the simultaneous expression of HA and NA along with a viral core protein, such as influenza matrix (M1) or a retroviral Gag protein.
openaire +2 more sources
Cross-Protection Induced by Virus-like Particles Derived from the Influenza B Virus
Biomedicines, 2022 The mismatch between the circulating influenza B virus (IBV) and the vaccine strain contributes to the rapid emergence of IBV infection cases throughout the globe, which necessitates the development of effective vaccines conferring broad protection. Here,
Hae-Ji Kang +5 more
doaj +1 more source
Atomic structures and deletion mutant reveal different capsid-binding patterns and functional significance of tegument protein pp150 in murine and human cytomegaloviruses with implications for therapeutic development. [PDF]
, 2019 Cytomegalovirus (CMV) infection causes birth defects and life-threatening complications in immunosuppressed patients. Lack of vaccine and need for more effective drugs have driven widespread ongoing therapeutic development efforts against human CMV (HCMV)
Balogun, Rilwan +9 more
core +2 more sources
Virus-like particles as vaccine adjuvants
Molecular Biotechnology, 2001 Virus-like particles (VLPs) consist of one or more viral coat proteins that assemble into particles. They can be taken up by antigen presenting cells (APC), peptides derived from them are presented on MHC class I molecules at the cell surface, and thereby prime a CD8+ T cell response, either against the particle-forming protein itself (such as ...
openaire +3 more sources
A synthetic biology approach for a vaccine platform against known and newly emerging serotypes of bluetongue virus [PDF]
, 2014 Bluetongue is one of the major infectious diseases of ruminants and is caused by Bluetongue virus (BTV), an arbovirus existing in nature in at least 26 distinct serotypes. Here, we describe the development of a vaccine platform for BTV.
Brunet, Silvie +6 more
core +2 more sources
Zika virus-like particle (VLP) based vaccine
PLOS Neglected Tropical Diseases, 2017 The newly emerged mosquito-borne Zika virus poses a major public challenge due to its ability to cause significant birth defects and neurological disorders. The impact of sexual transmission is unclear but raises further concerns about virus dissemination.
Hélène Boigard +5 more
openaire +4 more sources